Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Family Matters: Tips and Guidance for Effective Nurturing and Everyday Life - 2German finance minister seeks better market access in China talks
- 3Israel approves 19 new West Bank settlements in major annexation push
- 4Novo Nordisk slashes prices of popular weight loss and diabetes drugs
- 5Reports: Germany plans expansion of foreign intelligence powers
- Israel says soldiers wounded in Gaza fighting amid fragile truce
- Find the Mysteries of Effective Objective Setting: Transforming Dreams into Feasible Targets
- Two Israeli infants among wounded by shrapnel in overnight Iranian missile barrage
- Court clears Beersheba assault suspect of link to Haymanut Kasau disappearance, extends detention
- West Antarctica’s history of rapid melting foretells sudden shifts in continent’s ‘catastrophic’ geology
- What's your biological age? Experts explain the benefits and risks of at-home tests
- Most normal matter in the universe isn't found in planets, stars or galaxies – an astronomer explains where it's distributed
- NASA's giant moon rocket, in photos
- People can't get enough of this couple's Hallmark movie reviews. They don't know the painful backstory.
